Prosecution Insights
Last updated: July 17, 2026
Application No. 18/111,316

STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES

Non-Final OA §112
Filed
Feb 17, 2023
Priority
Aug 19, 2020 — provisional 63/067,726 +5 more
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Atea Pharmaceuticals, Inc.
OA Round
2 (Non-Final)
61%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
912 granted / 1495 resolved
+1.0% vs TC avg
Strong +43% interview lift
Without
With
+43.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
46 currently pending
Career history
1533
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
43.8%
+3.8% vs TC avg
§102
4.8%
-35.2% vs TC avg
§112
11.0%
-29.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1495 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-55 are pending as of the response and amendments filed on 4/6/26. Claims 1-16 and 41-49 are withdrawn from consideration as being directed to non-elected inventions, claims 54-55 have been newly added. Claims 17-40 and 50-55 are currently under examination. The previous rejection of claims 17-40 and 50-53 under 35 USC 112(b) is withdrawn in consideration of the amendments. However, a new rejection under 35 USC 112(b) is made upon consideration of the amended claims, discussed below. Claims 17-40 and 50-55 were examined. Claims 37-38 and 54-55 are rejected. Claims 17-40 and 50-53 are allowed. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 37-38 and 54-55 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 37 recites numerous organic solvents selected from C1-8 alcohol, C2-8 ether, C3-7 ester, C2-7 nitrile, and an antisolvent, however claim 36, from which claim 37 depends from doesn’t recite the solvent to be selected from any of the above. Claim 36 recites the solvent to be selected from an alkyl acetate, a chlorinated solvent, and a ketone, therefore the limitations of claim 37 lack antecedent basis, and the claim is indefinite. Claims 38 and 54-55 are similarly rejected as these claims depend directly or indirectly from claim 37. It is suggested claim 37 be amended to depend from claim 32 to overcome this rejection. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Feb 17, 2023
Application Filed
Jan 05, 2026
Non-Final Rejection mailed — §112
Apr 06, 2026
Response Filed
Apr 23, 2026
Final Rejection mailed — §112
Jun 23, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12653823
PHARMACEUTICAL COMPOSITION
3y 0m to grant Granted Jun 16, 2026
Patent 12648945
COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
3y 3m to grant Granted Jun 09, 2026
Patent 12636283
INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS
5y 4m to grant Granted May 26, 2026
Patent 12629352
METHODS AND USES FOR APELIN RECEPTOR AGONISTS
4y 2m to grant Granted May 19, 2026
Patent 12630504
PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE
3y 3m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+43.1%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1495 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month